Amanote Research
Register
Sign In
Pss44 - An Evaluation of the Current Treatment Pathways and Associated NHS Resource Use for the Management of Uncontrolled Moderate-To-Severe Atopic Dermatitis in Secondary Care
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2544
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
M. Ameen
S. George
C. Harwood
R. Weller
J. Lear
R. Hudson
R. Rout
K. Halsby
A. Bewley
Publisher
Elsevier BV
Related search
Efficacy and Safety of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults
Oncotarget
Oncology
Guidelines of Care for the Management of Atopic Dermatitis
Journal of the American Academy of Dermatology
Dermatology
New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
Children
Pharmacoeconomic Analysis of Using Biological Agents for Uncontrolled Moderate-To-Severe Atopic Asthma in the Russian Federation
FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology
Effect of Moderate to Severe Atopic Dermatitis on the Prognosis of Egg Allergy Resolution
Asian Pacific Journal of Allergy and Immunology
Medicine
Allergy
Immunology
OC08 – Care for the Children With Severe Forms of Atopic Dermatitis
Nursing children and young people
Medicine
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-To-Severe Atopic Dermatitis
Journal of Cutaneous Medicine and Surgery
Dermatology
Surgery
Dupilumab Versus Cyclosporine for Treatment of Moderate-To-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
Acta Dermato-Venereologica
Dermatology
Medicine
After the Approval of Dupilumab for Moderate-To-Severe Atopic Dermatitis: What Is Next on the Research Agenda?
British Journal of Dermatology
Dermatology
Medicine
